瑞博生物技术股份有限公司 focuses on the research and development of small nucleic acid drug delivery technologies and chemical modifications. It has established a drug development platform that integrates various technologies for small nucleic acids, supporting the lifecycle from early research to industrialization.

瑞博生物技术股份有限公司

Suzhou Ribo Life Science Co., Ltd | 356 followers on LinkedIn. Dedicated to Innovative Oligonucleotide Therapeutics to Improve Human Health and Wellbeing | Established in 2007, Suzhou Ribo Life Science Co., Ltd. (Ribo) is a clinical stage company devoted to the development of innovative RNAi technologies  and oligonucleotide therapeutics as an effort to address unmet clinical needs in the world with the tools, capacity and RNA therapeutics that we build up in China. Fueled by our mission to make China&#39;s oligonucleotide therapeutics serve the world, we seek.

CHINA HEALTHCARE BUSINESS DEVELOPMENT ASSOCIATION

Sam Ma

Suzhou Ribo Life Science Ltd. - VP

Shan Gao

Vice President

Hong Yu

Finance Controller at Suzhou Ribo Life Science Co.,Ltd

Jane Gu

Suzhou Ribo Life Science Co., Ltd

Great mielstone to step into rare disease!

Ribo and Qilu Announce Licensing Agreement for siRNA Therapeutic Targeting PCSK9

We are very pleased to announce this strategic collaboration, leveraging our innovative siRNA technology platform to deliver next-generation treatments for patients with liver diseases.

Metric
Company Name	瑞博生物技术股份有限公司
Symbol
MSH ID	COM:RIBOLIA
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	CN
Stage
Employee Count
Website	ribolia.com
LinkedIn	suzhou-ribo-life-science-ltd-co
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

RIBO

COM:RIBOLIA

瑞博生物技术股份有限公司

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue